EXPEREO
17.4.2024 09:01:29 CEST | Business Wire | Press release
Expereo, the intelligent internet company that connects people, places and things anywhere, has today announced the enhancement of their connectivity portfolio with Fixed Wireless Access. This latest innovation from Expereo equips businesses with direct access to wireless networks across 190 countries, enabling business continuity through network resilience, and growth through fast and agile deployment and access in remote locations.
Fixed Wireless Access (FWA) is a cost-efficient reliable alternative for business continuity in the event of fixed line network outages. These can happen from time to time, often through cables being cut, or hardware or software failures. For those business critical sites that cannot afford any downtime, Fixed Wireless Access provides a technology diverse, cost effective, reliable continuity option, avoiding the need to deploy a second fixed line. With a vendor agnostic solution, businesses can be confident they will always connect to the strongest possible mobile network when they need to.
Fixed Wireless Access is also perfect for fast, agile deployments often being installed within weeks rather than months, enabling businesses to rapidly connect their operations to capitalise on new growth opportunities while waiting for fixed line deployments. Additionally Fixed Wireless Access can be used as a primary connectivity option in areas that are temporary, hard to reach or remote. This enables growing businesses to establish branch offices or field locations in hard-to-reach areas where wired connections are not available or even possible.
A key differential is the integration of Fixed Wireless Access into Expereo’s customer experience platform, expereoOne, offering businesses a complete, intuitive view of their Global Internet and SD-WAN estate. For Fixed Wireless Access, this means that IT Teams have complete visibility of their monthly invoices and an up-to-date status of all data pools and bundles, as well as signal strength, signal quality and the carriers providing the connectivity. A complete view whenever they need it.
Sander Barens, Chief Product Officer at Expereo, comments:
“Today, always on internet connectivity is essential for business growth and efficiency.
One size does not fit all, and enterprise businesses need to deploy a connectivity strategy to meet today’s challenges. Fixed access will always be the driving force of connectivity, but it’s not always the best solution. When you need to be up and running quickly or in a remote location, that is when Fixed Wireless Access comes into play - fast deployments wherever you need it.
Connectivity solutions no longer need to be either/or, when you work with a partner who understands your connectivity needs and has the portfolio, experience and global coverage to help you set the strategy for your business you can rest easy that your business will be connected 24/7 around the globe.”
To find out more about Fixed Wireless Access, please visit : https://www.expereo.com/service/fixed-wireless-access.
About Expereo
Expereo is the intelligent internet company that connects people, places and things anywhere. Solutions include Global Internet, SD-WAN/SASE, and Enhanced Internet. With an extensive global reach, Expereo is the trusted partner of 60% of Fortune 500 companies. It powers enterprise and government sites in more than 190 countries, with the ability to connect to 600,000 locations worldwide, working with over 2,300 partners to help customers improve productivity and empowering their networks and cloud services with the agility, flexibility and value of the Internet, with optimal network performance.
Expereo was acquired in Feb 2021, by Vitruvian Partners. The international growth capital and buyout firm, acquired a majority shareholding from leading European private equity firm, Seven2.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417736251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
